



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: January 18, 2008

To: Primary Clinical Research Associates

From: Daniel V. Satele
Protocol Development Coordinator

Re: N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR[®] Depot) for Symptomatic Ascites in Cancer Patients

A new forms packet is being distributed as the previous version was missing the Baseline VEGF Specimen Submission Form. Please replace any previous versions of this packet with the new version.

If you have any questions, please feel free to contact me at 507/266-3465.

Thank you.

DS/dg